{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:44:11Z","timestamp":1782816251259,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The prognosis of adrenocortical carcinoma (ACC) is poor but highly variable. The present study aimed to characterize patients with ACC at a single center in Taiwan and to determine the prognostic predictors of overall and progression-free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records of patients, who were diagnosed with ACC at Taipei Veterans General Hospital between January 1992 and June 2021, were reviewed. Patient demographics, tumor characteristics, and subsequent treatment were analyzed with regard to overall survival and progression-free survival using Kaplan-Meier methods and a Cox regression model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixty-seven patients were included. Females (65.7%) were more susceptible to ACC, with a younger onset and active hormonal secretion. One-half of the patients exhibited distant metastases at the time of diagnosis. The European Network for the Study of Adrenal Tumours (ENSAT) stage (hazard ratio [HR] 3.60 [95% confidence interval (CI) 1.25\u201310.38]; p=0.018), large vessel invasion (HR 5.19 [95% CI 1.75\u201315.37]; p=0.003), and mitotane use (HR 0.27 [95% CI 0.11\u20130.70]; p=0.007) were significantly associated with overall survival (OS). There was no single factor independently associated with progression-free survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ENSAT stage had a substantial impact on overall survival though there was no difference in OS between patients with stage II and stage III ACC. Large vessel invasion portended poor prognosis and influenced OS significantly. Moreover, mitotane only improved clinical outcomes of patients with stage IV disease.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1134643","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T05:35:17Z","timestamp":1678426517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Li-Hsin","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chueh-Chuan","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ning","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23886","article-title":"Adrenocortical carcinoma in the united states: treatment utilization and prognostic factors","volume":"113","author":"Bilimoria","year":"2008","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0723","article-title":"Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma","volume":"158","author":"Hermsen","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab866","article-title":"Pathological and genetic stratification for management of adrenocortical carcinoma","volume":"107","author":"Clay","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: An analysis from the national cancer database","volume":"103","author":"Tella","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S187169","article-title":"Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2015.4516","article-title":"Nomograms to predict recurrence-free and overall survival after curative resection of adrenocortical carcinoma","volume":"151","author":"Kim","year":"2016","journal-title":"JAMA Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12894-015-0038-1","article-title":"Survival and prognostic factors for adrenocortical carcinoma: A single institution experience","volume":"15","author":"Loncar","year":"2015","journal-title":"BMC Urol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2730","article-title":"Clinical and biological features in the prognosis of adrenocortical cancer: Poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients","volume":"91","author":"Abiven","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.006","article-title":"Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer","volume":"65","author":"Berruti","year":"2014","journal-title":"Eur Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000336134","article-title":"Surgical management and clinical prognosis of adrenocortical carcinoma","volume":"88","author":"Dong","year":"2012","journal-title":"Urol Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.path.2019.08.010","article-title":"Treatment of adrenocortical carcinoma","volume":"12","author":"Vaidya","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.12.007","article-title":"The European network for the study of adrenal tumors staging system is prognostically superior to the international union against cancer-staging system: A north American validation","volume":"46","author":"Lughezzani","year":"2010","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma: Proposal for a revised TNM classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-001-0047-y","article-title":"Adrenocortical carcinomas: Surgical trends and results of a 253-patient series from the French association of endocrine surgeons study group","volume":"25","author":"Icard","year":"2001","journal-title":"World J Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5536-1","article-title":"Lymphadenectomy for adrenocortical carcinoma: Is there a therapeutic benefit","volume":"23","author":"Gerry","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-13-0142","article-title":"Surgery for adrenocortical carcinoma in the Netherlands: Analysis of the national cancer registry data","volume":"169","author":"Kerkhofs","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2012.02.005","article-title":"Surgery in adrenocortical carcinoma: Importance of national cooperation and centralized surgery","volume":"152","author":"Hermsen","year":"2012","journal-title":"Surgery"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.3390\/cancers14163904","article-title":"The overall survival and progression-free survival in patients with advanced adrenocortical cancer is increased after the multidisciplinary team evaluation","volume":"14","author":"Tizianel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4900-x","article-title":"Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: A meta-analysis of surgical and oncological outcomes","volume":"23","author":"Autorino","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2015.12.013","article-title":"Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: A 13-institution study by the US adrenocortical carcinoma group","volume":"222","author":"Postlewait","year":"2016","journal-title":"J Am Coll Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab048.336","article-title":"Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients","volume":"5","author":"Terzolo","year":"2021","journal-title":"J Endocrine Soc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.183","article-title":"Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients","volume":"69","author":"Haak","year":"1994","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111850","article-title":"Mitotane concentrations influence the risk of recurrence in adrenocortical carcinoma patients on adjuvant treatment","volume":"8","author":"Puglisi","year":"2019","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235901","article-title":"Advanced adrenocortical carcinoma: From symptoms control to palliative care","volume":"14","author":"Ruggiero","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2010.09.024","article-title":"Adrenocortical carcinoma: The influence of large vessel extension","volume":"148","author":"Turbendian","year":"2010","journal-title":"Surgery"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.surg.2005.05.014","article-title":"Adrenocortical carcinoma extending into the inferior vena cava: Presentation of a 15-patient series and review of the literature","volume":"139","author":"Chiche","year":"2006","journal-title":"Surgery"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0196","article-title":"Characteristics of adrenocortical carcinoma in south Korea: A registry-based nationwide survey","volume":"9","author":"Lim","year":"2020","journal-title":"Endocr Connect"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1134643\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T05:35:20Z","timestamp":1678426520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1134643\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":32,"alternative-id":["10.3389\/fendo.2023.1134643"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1134643","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"article-number":"1134643"}}